Supply & Distribution
Supply & Distribution/Inventory & Stock Health
Inventory & Stock Health
Stock availability, cover, movement and supply risk across products and wholesalers.
1 – 30 Jun 2026·All Divisions·All Regions·All Categories·All Wholesalers
Measure
Cover
Scope
View
Orbit Inventory Briefing
Updated 14 min ago
Inventory remains broadly stable, but 14 products are below their approved stock-cover threshold. Cardiaxol 20mg is projected to stock out within nine days at three wholesalers, while Respireze Inhaler is overstocked at Wholesaler A. Approximately R3.4m of revenue is exposed, with a viable redistribution opportunity across two regions worth R1.1m.
Total Stock-on-Hand
R46.8m
+3.1% vs prev period
Average Stock Cover
1.5 mo
-0.2 mo vs prev period
Low-Stock Products
14
Rising+4 vs prev period
Excess-Stock Products
9
Excess+2 vs prev period
Revenue at Risk
R3.4m
Elevated+R0.8m vs prev period
Redistribution Opportunity
R1.1m
ActionableAcross 3 products
Product × Wholesaler stock health
Days of cover · click a product to inspect
| Product | W. A | W. B | W. C | NDG | RHS |
|---|---|---|---|---|---|
12d | 22d | 9d | 18d | 8d | |
26d | 34d | 14d | 28d | 11d | |
74d | 41d | 11d | 33d | 22d | |
31d | 27d | 24d | 30d | 26d | |
62d | 44d | 38d | 51d | 29d | |
9d | 16d | 12d | 21d | 14d |
Critical low
Warning
Healthy
Excess
Stock-cover distribution
Products by days of cover
Critical
Warning
Healthy
Excess
Lowest stock cover
Fastest-approaching stockouts
Highest excess stock
Cover well above threshold
Stock movement — Cardiaxol 20mg
On-hand vs demand & minimum
On-hand
Demand
Minimum
Projected to fall below minimum in W28 — 9 days to stockout.
Redistribution opportunities
Orbit-recommended stock transfers
Respireze Inhaler
Wholesaler AWholesaler C
+R0.42m
600 units
Wholesaler A: 74d → 51d
Wholesaler C: 11d → 28d
Neurospen 500
Wholesaler ARegional Health Supply
+R0.18m
320 units
Wholesaler A: 62d → 44d
Regional Health Supply: 8d → 24d
Metaform 850
Wholesaler BWholesaler C
+R0.14m
420 units
Wholesaler B: 48d → 34d
Wholesaler C: 12d → 22d
Risks & opportunities
Prioritised for this period
Risks
Cardiaxol projected to stock out in 9 daysR2.4m
Four high-value products below minimum cover4 SKUs
Backorders increasing on Respireze+R0.6m
Low availability in Gauteng North-14 pp
Opportunities
Excess Respireze available for redistribution+R0.42m
Strong Western Cape demand supports replenishment+R0.9m
Two products healthy but low distribution+R0.6m
Slow stock could redirect to demand accounts+R0.3m
Detailed inventory
By product & wholesaler — with recommended action
| Product | Brand | Wholesaler | On-Hand | Available | Avg Sales | Cover | Min | Max | Sell-thru | BO | Risk | Action |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cardiaxol 20mg | Cardiaxol | Wholesaler C | 3,400 | 3,100 | 380/d | 9d | 20 | 45 | 92% | 1,200 | critical | Expedite next batch |
| Cardiaxol 40mg | Cardiaxol | Regional Health Supply | 1,800 | 1,650 | 160/d | 11d | 20 | 45 | 88% | 480 | critical | Escalate replenishment |
| Respireze Inhaler | Respireze | Wholesaler A | 9,200 | 8,800 | 124/d | 74d | 25 | 55 | 62% | — | warning | Redistribute to Wholesaler C |
| Respireze Inhaler | Respireze | Wholesaler C | 620 | 540 | 56/d | 11d | 25 | 55 | 91% | 340 | critical | Receive redistribution |
| Gastraven 20mg | Gastraven | Wholesaler B | 5,200 | 4,900 | 190/d | 27d | 20 | 45 | 89% | — | success | Sustain |
| Neurospen 500 | Neurospen | Wholesaler A | 7,100 | 6,900 | 114/d | 62d | 20 | 45 | 58% | — | warning | Reduce inbound; promote to independents |
| Pulmavent DPI | Pulmavent | Wholesaler A | 810 | 720 | 90/d | 9d | 20 | 40 | 84% | 260 | critical | Escalate to supply planning |
| Metaform 850 | Metaform | Wholesaler B | 4,400 | 4,200 | 92/d | 48d | 20 | 45 | 71% | — | warning | Slow replenishment |